Table 3.
Association of Donor UMOD and OPN with Risk of Death-Censored Graft Failure and All-Cause Graft Failure
| Hazard Ratio (95% Confidence Interval) | |||
|---|---|---|---|
|
| |||
| Mean (95% CI) Event Rate per 1000 Person Year | Unadjusted | Adjusteda | |
| Death-Censored Graft Failure (dcGF) | |||
|
| |||
| Uromodulin | |||
|
| |||
| Log2 (n=2430) | 33 (29.6, 36.9) | 1.11 (1.03, 1.19) | 1.1 (1.02, 1.2) |
| Tertile 1 (n=810) | 28.6 (23.2, 35.2) | 1 (ref) | 1 (ref) |
| Tertile 2 (n=810) | 33.9 (28.1, 41) | 1.19 (0.9, 1.57) | 1.12 (0.84, 1.5) |
| Tertile 3 (n=810) | 36.4 (30.4, 43.6) | 1.27 (0.96, 1.67) | 1.2 (0.89, 1.62) |
|
| |||
| Osteopontin | |||
|
| |||
| Log2 (n=2430) | 33 (29.6, 36.9) | 0.95 (0.89, 1) | 0.94 (0.88, 1) |
| Tertile 1 (n=810) | 38.6 (32.2, 46.2) | 1 (ref) | 1 (ref) |
| Tertile 2 (n=810) | 29.9 (24.4, 36.5) | 0.78 (0.59, 1.02) | 0.82 (0.61, 1.08) |
| Tertile 3 (n=810) | 31 (25.5, 37.7) | 0.8 (0.62, 1.05) | 0.76 (0.56, 1.04) |
|
| |||
| All-Cause Graft Failure (GF) | |||
|
| |||
| Uromodulin | |||
|
| |||
| Log 2 (n=2430) | 65.7 (60.8, 71.1) | 1.06 (1, 1.12) | 1.07 (1.01, 1.13) |
| Tertile 1 (n=810) | 60.1 (52.1, 69.4) | 1 (ref) | 1 (ref) |
| Tertile 2 (n=810) | 66.9 (58.5, 76.6) | 1.11 (0.91, 1.36) | 1.12 (0.91, 1.37) |
| Tertile 3 (n=810) | 70 (61.4, 79.8) | 1.13 (0.93, 1.37) | 1.16 (0.95, 1.43) |
|
| |||
| Osteopontin | |||
|
| |||
| Log2 (n=2430) | 65.7 (60.8, 71.1) | 0.96 (0.93, 1) | 0.95 (0.91, 1) |
| Tertile 1 (n=810) | 71.8 (62.9, 82) | 1 (ref) | 1 (ref) |
| Tertile 2 (n=810) | 64.7 (56.5, 74.1) | 0.89 (0.74, 1.08) | 0.86 (0.7, 1.05) |
| Tertile 3 (n=810) | 61 (53, 70.1) | 0.83 (0.68, 1) | 0.77 (0.61, 0.96) |
Adjusted for urine creatinine, KDRI, and the following clinical covariates: cold ischemia time (22 missing), recipient age (years), race, sex, prior kidney transplant, diabetes as the cause of end-stage kidney disease, number of human leukocyte antigen mismatches, panel reactive antibody (%), body mass index (1 missing), and pre-emptive transplant
There were no significant interactions by donor AKI status in the relationship between UMOD and dcGF and GF.
Complete case analysis was completed since missing data was rare. Biomarker measurements and outcomes were available in all recipients. Covariate data was complete except for cold ischemia time (0.9% missing), HLA mismatch (0.2% missing) and BMI (0.04% missing).